Immunotherapy for rheumatoid arthritis

Current Opinion in Immunology

Volumn 13, Issue 5, 2001, Pages 611-616

  Taylor, P C ^a   Williams, R O ^a   Maini, R N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; C REACTIVE PROTEIN; CD40 ANTIGEN; CELL SURFACE PROTEIN; CHEMOATTRACTANT; CYCLOSPORIN; CYTOKINE ANTIBODY; ETANERCEPT; GAMMA INTERFERON; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT CYTOKINE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY SPECIFICITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0035479828     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00269-7     Document Type: Review

References (57)

1. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
2. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
3. Anti-cytokine therapy in rheumatoid arthritis
4. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
5. Cartilage destruction and bone erosion in arthritis: The role of tumour necrosis factor alpha
6. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
7. Arguments for interleukin 1 as a target in chronic arthritis
8. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra
9. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy
10. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
11. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
12. Infliximab and methotrexate in the treatment of rheumatoid arthritis
13. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
14. Anti-TNF therapies
15. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
16. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Findings in open-label and randomized placebo-controlled trials
17. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
18. Dose-range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
19. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
20. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis
21. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
22. A multicenter, double-blind, dose-ranging, randomised, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores
23. Treatment of interleukin-1 receptor antagonist in combination with methotrexate in rheumatoid arthritis patients
24. IL-10, T-lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor
25. Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist
26. Two inhibitors of pro-inflammatory cytokine release, IL-10 and Il-4, have contrasting effects on release of soluble p75 TNF receptor by cultured monocytes
27. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
28. Interleukin-10 inhibition of the progression of established collagen-induced arthritis
29. rHUIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study
30. RHuIL-10 (TENOVIL) plus methotrexate (MTX) in active rheumatoid arthritis: A phase I/II study
31. rHuIL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study
32. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction
33. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
34. An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis
35. A randomised double-blind study comparing L4 treatment with recombinant interferon gamma versus placebo in the treatment of RA
36. The effects of interferon beta treatment on arthritis
37. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy
38. Recombinant human interleukin 6 (IL-6/BSF-2/HFS) regulates the synthesis of acute phase proteins in human hepatocytes
39. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6
40. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
41. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody
42. A proinflammatory role for IL-18 in rheumatoid arthritis
43. Reduced incidence of collagen-induced arthritis in mice lacking IL-18
44. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis
45. IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis
46. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology
47. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
48. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis
49. Combination therapy in mice: What can we learn that may be useful for understanding rheumatoid arthritis?
50. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2
51. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis
52. Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody
53. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process
54. Selective depletion of myelin-reactive T-cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis
55. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis
56. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models rheumatoid arthritis
57. Combination therapy with DMARDs and biological agents in collagen-induced arthritis